Future Directions in the Management of Immune Thrombocytopenia
Expert panelists reflect on the advent of newer therapies in immune thrombocytopenia and look toward future evolutions in care.
Other Novel Therapeutic Agents in Immune Thrombocytopenia
Before closing out their discussion on novel treatment approaches in ITP, experts review data behind FcR-, BTK-, and CD38-targeted therapies.
Novel Treatment Strategies in Immune Thrombocytopenia: Complement Inhibitors
Panelists review data behind sutimlimab, a complement inhibitor being investigated in the setting of immune thrombocytopenia.
Novel Treatment Strategies in Immune Thrombocytopenia: Frontline Use of TPO-RAs
Shared insight on clinical trials investigating the frontline use of thrombopoietin receptor agonists in patients with immune thrombocytopenia.
Treating Patients With Immune Thrombocytopenia in the Era of COVID-19
A brief review of how the management of patients with immune thrombocytopenia has been impacted by the COVID-19 pandemic.
How Does Treatment Duration Impact Outcomes in ITP?
Experts consider how treatment duration can impact patient outcomes in immune thrombocytopenia and discuss discontinuation of TPO-Ras.
Risk of Thrombosis With TPO-RAs in Immune Thrombocytopenia
Comprehensive discussion on nuancing the risk of thrombosis with thrombopoietin receptor agonists in immune thrombocytopenia.
Use of Romiplostim in Chronic Immune Thrombocytopenia
Considerations for the uptake and use of romiplostim, an injectable thrombopoietin receptor agonist, in immune thrombocytopenia.
Data on Avatrombopag in Chronic ITP
A commentary on clinical experience with avatrombopag, another oral TPO-RA, in treating ITP.
Eltrombopag in Chronic Immune Thrombocytopenia
Expert panelists consider clinical trial data on and personal experience with using eltrombopag, an oral TPO-RA, in immune thrombocytopenia.
Selecting an Oral TPO-RA for Chronic Immune Thrombocytopenia
A brief discussion of factors that influence selection of oral versus injectable TPO-RA therapy for ITP.
Thrombopoietin Receptor Agonists in Pediatric Immune Thrombocytopenia
Shared insight on thrombopoietin receptor agonist (TPO-RA) use in the pediatric setting of immune thrombocytopenia management.
Chronic Immune Thrombocytopenia: Considerations for Fostamatinib Therapy
Expert perspectives on the selection and use of fostamatinib as second-line therapy in patients with immune thrombocytopenia.
Use of Rituximab Therapy in Chronic Immune Thrombocytopenia
Focusing on second-line systemic agents in immune thrombocytopenia, experts review the historical use of rituximab therapy.
What is the Role of Splenectomy in Chronic Immune Thrombocytopenia?
Panelists consider when they would select splenectomy over second-line systemic therapy in patients with immune thrombocytopenia.
Defining Chronic or Persistent Immune Thrombocytopenia
Expert perspectives on how to identify chronic or persistent disease in patients diagnosed with immune thrombocytopenia.
The Significance of Patient Age in Treatment and Management of ITP
A commentary on the significance of the patient’s age in treating and managing ITP.
Optimizing Frontline Therapy in ITP: Treatment Selection and Goals
Shared insight on treatment goals for immune thrombocytopenia and how physicians might optimally select frontline therapy.
Making a Diagnosis of Immune Thrombocytopenia
Opening their discussion on immune thrombocytopenia (ITP), expert panelists review criteria for diagnosis and highlight differences between adult and pediatric populations.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.